Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Pacira BioSciences Inc (NASDAQ: PCRX) closed at $26.67 down -0.67% from its previous closing price of $26.85. In other words, the price has decreased by -$0.67 from its previous closing price. On the day, 0.62 million shares were traded. PCRX stock price reached its highest trading level at $26.95 during the session, while it also had its lowest trading level at $26.17.
Ratios:
For a deeper understanding of Pacira BioSciences Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.24. For the most recent quarter (mrq), Quick Ratio is recorded 1.91 and its Current Ratio is at 2.38. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.55.
On January 30, 2025, Truist Upgraded its rating to Hold which previously was Sell and also upped its target price recommendation from $8 to $25. Truist Downgraded its Buy to Sell on August 13, 2024, whereas the target price for the stock was revised from $30 to $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 07 ’25 when BIGAL MARCELO sold 4,912 shares for $23.67 per share. The transaction valued at 116,267 led to the insider holds 11,393 shares of the business.
BIGAL MARCELO bought 4,912 shares of PCRX for $116,279 on Aug 07 ’25. On Jun 04 ’25, another insider, RIKER LAUREN, who serves as the Senior Vice President, Finance of the company, sold 5,578 shares for $26.21 each. As a result, the insider received 146,208 and left with 59,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1198355072 and an Enterprise Value of 1383894656. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.70 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 1.961 whereas that against EBITDA is 8.735.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.43, which has changed by 0.756917 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $27.64, while it has fallen to a 52-week low of $12.61. The 50-Day Moving Average of the stock is 12.47%, while the 200-Day Moving Average is calculated to be 14.54%.
Shares Statistics:
For the past three months, PCRX has traded an average of 641.26K shares per day and 618380 over the past ten days. A total of 44.90M shares are outstanding, with a floating share count of 42.79M. Insiders hold about 4.91% of the company’s shares, while institutions hold 115.92% stake in the company. Shares short for PCRX as of 1755216000 were 6288411 with a Short Ratio of 9.81, compared to 1752537600 on 5461498. Therefore, it implies a Short% of Shares Outstanding of 6288411 and a Short% of Float of 20.07.
Earnings Estimates
The dynamic stock of Pacira BioSciences Inc (PCRX) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.86, with high estimates of $0.94 and low estimates of $0.8.
Analysts are recommending an EPS of between $2.97 and $2.78 for the fiscal current year, implying an average EPS of $2.87. EPS for the following year is $3.26, with 6.0 analysts recommending between $3.52 and $2.82.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $182.86M this quarter.It ranges from a high estimate of $187.3M to a low estimate of $179.13M. As of the current estimate, Pacira BioSciences Inc’s year-ago sales were $168.57MFor the next quarter, 6 analysts are estimating revenue of $204.93M. There is a high estimate of $209.9M for the next quarter, whereas the lowest estimate is $201.13M.
A total of 6 analysts have provided revenue estimates for PCRX’s current fiscal year. The highest revenue estimate was $743.5M, while the lowest revenue estimate was $731.33M, resulting in an average revenue estimate of $737.83M. In the same quarter a year ago, actual revenue was $700.97MBased on 6 analysts’ estimates, the company’s revenue will be $812.06M in the next fiscal year. The high estimate is $829.6M and the low estimate is $785.2M.
